Home » In The News » Bold Therapeutics Successfully Initiates Clinical Trial of First-in-Class Anti-Cancer Agent BOLD-100
We use cookies to store and access device information so we can provide you with the best possible web experience. Your consent allows us to process data such as your browsing behaviour. Disabling cookies may adversely affect some of our website’s features and functions.
The JGH Foundation is currently working with a third-party vendor called Public Outreach to conduct a monthly giving campaign. This vendor clearly identifies itself as working on behalf of the JGH Foundation and meets our rigorous standards regarding data sharing and information privacy. If you have any questions, please contact us at 514-340-8251.
